We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > MN-166

News List

MediciNova Receives Notice of Allowance for Second Patent Covering Glioblastoma Treatment americanpharmaceuticalreview
April 24, 2020
MediciNova has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of glioblastoma.
MediciNova to Develop Severe Pneumonia, ARDS Treatment americanpharmaceuticalreview
March 11, 2020
MediciNova announced it plans to initiate development of MN-166 (ibudilast) for severe pneumonia and acute respiratory distress syndrome (ARDS).
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS drugs
April 25, 2019
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS.